There is an urgent need to expand access to Alzheimer’s disease testing, Schaeffer Institute Founding Director Dana Goldman writes in an op-ed for RealClearHealth.

Goldman argues that new blood tests that detect Alzheimer’s disease earlier and more accurately will enable intervention at an earlier stage, better care planning, and more effective use of emerging therapies.

Read more HERE